DE2360889A1 - Pharmazeutisches mittel - Google Patents
Pharmazeutisches mittelInfo
- Publication number
- DE2360889A1 DE2360889A1 DE2360889A DE2360889A DE2360889A1 DE 2360889 A1 DE2360889 A1 DE 2360889A1 DE 2360889 A DE2360889 A DE 2360889A DE 2360889 A DE2360889 A DE 2360889A DE 2360889 A1 DE2360889 A1 DE 2360889A1
- Authority
- DE
- Germany
- Prior art keywords
- pharmaceutical agent
- agent according
- pharmaceutical
- weight
- glycirrhetinic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title description 2
- 229940127557 pharmaceutical product Drugs 0.000 title description 2
- 239000002253 acid Substances 0.000 claims description 17
- 239000008177 pharmaceutical agent Substances 0.000 claims description 8
- 229940069428 antacid Drugs 0.000 claims description 7
- 239000003159 antacid agent Substances 0.000 claims description 7
- 230000001458 anti-acid effect Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- -1 aluminum compound Chemical class 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 238000004040 coloring Methods 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 230000001562 ulcerogenic effect Effects 0.000 claims 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000395 magnesium oxide Substances 0.000 description 3
- 239000000391 magnesium silicate Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229940099273 magnesium trisilicate Drugs 0.000 description 3
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 3
- 235000019793 magnesium trisilicate Nutrition 0.000 description 3
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 3
- 235000019477 peppermint oil Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 229960002252 carbenoxolone sodium Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BQENDLAVTKRQMS-UHFFFAOYSA-L disodium;10-(3-carboxylatopropanoyloxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound [Na+].[Na+].C12C(=O)C=C3C4CC(C)(C([O-])=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB5835572A GB1401360A (en) | 1972-12-18 | 1972-12-18 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2360889A1 true DE2360889A1 (de) | 1974-06-20 |
Family
ID=10481403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2360889A Withdrawn DE2360889A1 (de) | 1972-12-18 | 1973-12-06 | Pharmazeutisches mittel |
Country Status (10)
| Country | Link |
|---|---|
| AU (1) | AU476390B2 (enExample) |
| BE (1) | BE802701A (enExample) |
| CA (1) | CA1018457A (enExample) |
| DE (1) | DE2360889A1 (enExample) |
| FR (1) | FR2210400B1 (enExample) |
| GB (1) | GB1401360A (enExample) |
| IE (1) | IE38521B1 (enExample) |
| IL (1) | IL42314A (enExample) |
| NL (1) | NL7317237A (enExample) |
| ZA (1) | ZA732439B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8307096A1 (es) * | 1981-06-01 | 1983-07-01 | Orion Yhtymae Oy | "un metodo para preparar tabletas a base de polvos de medicamento acidicos, inocuas para el esofago". |
| GB2122893B (en) * | 1982-06-30 | 1985-06-26 | Biorex Laboratories Ltd | Glycyrrhetinic acid compositions |
| AU553789B2 (en) * | 1982-06-30 | 1986-07-24 | Biorex Laboratories Ltd. | Glycyrrhetinic acid derivatives in cream compositions |
| US4861591A (en) * | 1987-11-18 | 1989-08-29 | American Home Products Corporation | Formulations for hygroscopic pharmaceuticals |
-
1972
- 1972-12-18 GB GB5835572A patent/GB1401360A/en not_active Expired
-
1973
- 1973-04-09 ZA ZA732439A patent/ZA732439B/xx unknown
- 1973-05-20 IL IL42314A patent/IL42314A/en unknown
- 1973-07-23 BE BE133790A patent/BE802701A/xx not_active IP Right Cessation
- 1973-07-30 FR FR7327833A patent/FR2210400B1/fr not_active Expired
- 1973-11-16 IE IE2082/73A patent/IE38521B1/xx unknown
- 1973-11-30 AU AU63127/73A patent/AU476390B2/en not_active Expired
- 1973-12-06 DE DE2360889A patent/DE2360889A1/de not_active Withdrawn
- 1973-12-17 CA CA188,350A patent/CA1018457A/en not_active Expired
- 1973-12-17 NL NL7317237A patent/NL7317237A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2210400B1 (enExample) | 1977-07-15 |
| IL42314A (en) | 1976-09-30 |
| GB1401360A (en) | 1975-07-16 |
| FR2210400A1 (enExample) | 1974-07-12 |
| IL42314A0 (en) | 1973-07-30 |
| ZA732439B (en) | 1974-03-27 |
| IE38521B1 (en) | 1978-03-29 |
| CA1018457A (en) | 1977-10-04 |
| AU476390B2 (en) | 1976-09-16 |
| AU6312773A (en) | 1975-06-05 |
| BE802701A (fr) | 1974-01-23 |
| IE38521L (en) | 1974-06-18 |
| NL7317237A (enExample) | 1974-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2226340C2 (enExample) | ||
| DE69218557T2 (de) | Stabile Zusammensetzung die ein Enalapril-Salz enthält, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE2360918A1 (de) | Pharmazeutisches mittel | |
| DE2822789C2 (de) | N-Acetyl-DL-methionin-(p-acetylaminophenyl)-ester, Verfahren zu seiner Herstellung und seine Verwendung | |
| DE2549783B2 (de) | Triglyceride mit entzündungshemmender Wirkung | |
| DE68915269T2 (de) | Polyvalentes entzündungshemmendes mittel. | |
| DE2040578C3 (de) | Analgetisch, antiinflammatorisch und antiulcerogen wirkendes Arzneimittel | |
| DE2360889A1 (de) | Pharmazeutisches mittel | |
| DE2140719A1 (de) | Arzneimittel auf der Grundlage eines Pyrazolons | |
| DE3038966A1 (de) | 3-benzoyl-2-nitrophenylessigsaeuren und ihre derivate, sowie ihre verwendung als entzuendungshemmende mittel | |
| DE2101378A1 (de) | Neue pharmazeutische Zusammensetzungen zur Behandlung von Bakterieninfektionen | |
| DE2748291C3 (de) | Substituierte 13-Benzodioxan-4one und Verfahren zu ihrer Herstellung sowie Verwendung dieser Verbindungen bei der Bekämpfung von Entzündungen | |
| DE3111770C2 (enExample) | ||
| DE2554902A1 (de) | Neue arzneimittelkombinationen und verfahren zu ihrer herstellung | |
| WO1998058639A1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE2461985C3 (de) | Pepsininhibierendes Arzneimittel | |
| DE3240650C2 (enExample) | ||
| DE1792447C3 (de) | Oral anwendbares, cytostatisches Mittel | |
| DE2535799C3 (de) | N'- [1 -(p-Chlorbenzoyl)-5-methoxy-2-methyl-3indolyl-acetoxy- alkyl] -N-(N-benzoyl- N'JS'-di-npropyl-DL-isoglutaminyloxy- alkyD-piperazine und diese enthaltene Entzündungen und Gelenksaffektionen hemmende Präparate | |
| DE602004003252T2 (de) | Verwendung von 2H-[1,3]-Oxazino[3,2]indol-Derivaten zur Behandlung von neuropathischem Schmerz | |
| DE69426317T2 (de) | Verwendung von Beta-Naphthochinonderivaten zur Hemmung von Blutplättchen-Aggregation | |
| DE1543733C3 (de) | Aluminium-bis-alpha-(p-chlorphenoxy) isobutyrat und diese Verbindung als Wirkstoff enthaltende Hellmittel | |
| EP3616518A1 (de) | Antimikrobielles mittel enthaltend isothiocyanate | |
| DE386760C (de) | Verfahren zur Herstellung eines kolloidal Ioeslichen Kieselsaeuregranulats | |
| AT397036B (de) | Verfahren zur entzündungsbehandlung mit antioxidativen metallorganischen verbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8141 | Disposal/no request for examination |